REG - Abingdon Health PLC - Vesting and Award of Options under LTIP
Today 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251204:nRSD1748Ka&default-theme=true
RNS Number : 1748K Abingdon Health PLC 04 December 2025
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Vesting and Award of Options under LTIP
York, UK 4 December 2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and regulatory services provider for
rapid diagnostic tests and med-tech, announces updates, under the terms of the
existing Long Term Incentive Plan established in December 2022 ("LTIP" or
the "Plan"). The Plan issues share options ("Options") over ordinary shares
of 0.025 pence each ("Ordinary Shares") to certain directors and senior
management, in order to incentivise and encourage retention in a manner that
aligns with the interests of the Company's shareholders.
Regarding the FY23 LTIP, 16% of the LTIPs awarded in December 2022 have now
vested against performance criteria for the financial year ended 30 June 2025
("FY25"), based on revenue and EBITDA targets. A total of 512,800 shares with
an exercise price of 7 pence have vested as illustrated below, with 2,692,199
LTIP shares from the FY23 scheme lapsing.
PDMR Role Options vested and exercisable under the FY23 LTIP (FY23-FY25 inclusive) Lapsed LTIP under the FY23 LTIP
Chris Hand Executive Chairman 68,571 360,000
Chris Yates Chief Commercial Officer President, Abingdon Health USA 205,714 1,080,000
Mark Jones Chief Operating Officer 96,000 504,000
Nina Garrett Chief Technical Officer 82,400 432,600
Candice Vendettuoli Director of QARA 45,714 240,000
Natalie Thrush Chief of Staff/Head of HR 14,400 75,600
In addition, under the terms of the Plan, the Company has awarded new nil
cost LTIPs totalling 3,361,000 shares which will vest circa October 2028,
following publication of audited accounts for the financial year ending 30
June 2028 ("FY28"), and subject to achieving performance targets based on
revenue and EBITDA for performance in FY28. 50% of these new awards are
based on achieving revenue targets and 50% are based on EBITDA targets.
New and existing LTIPs are summarised below:
PDMR Role Existing LTIPs less those lapsed from FY23 New FY26 LTIPs Total less lapsed FY23
Chris Hand Executive Chairman 1,298,057 946,000 2,244,057
Tom Hayes Chief Financial Officer 660,000 660,000 1,320,000
Chris Yates Chief Commercial Officer President, Abingdon Health USA 2,002,173 555,000 2,557,173
Mark Jones Chief Operating Officer 997,376 300,000 1,297,376
Nina Garrett Chief Technical Officer 839,556 300,000 1,139,556
Candice Vendettuoli Director of QARA 549,200 300,000 849,200
Natalie Thrush Chief of Staff/Head of HR 383,207 300,000 683,207
The total LTIP share options outstanding, less those which have now lapsed
from the FY23 scheme, from FY23, FY24, FY25 and FY26 is 10,090,570. If all
these LTIP options were to vest and be exercised this equates to 3.86% of
ordinary shares post exercise of options.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
Chris Hand, Executive Chairman Via Walbrook PR
Tom Hayes, CFO
Zeus (Sole Broker and Nominated Adviser) Tel: +44 (0)20 3829 5000
Antonio Bossi / Jacob Walker (Corporate Finance)
Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
(mailto:abingdon@walbrookpr.com)
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About Abingdon Health
Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.
The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format. Abingdon Health
has the internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion diagnostics,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK. Its consultancy services range from design, implementation and
maintenance of quality management systems, preparation of technical files for
regulatory approvals, part-time and interim management support, auditing both
internal and external, management reviews and presentations, training and
mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers
analytical testing and performance evaluation to generate the required
technical and data for regulatory approval for lateral flow and other in vitro
diagnostic assays from its Doncaster, England facilities.
Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.
Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
outlines the comprehensive support the Group can now provide to its
international customers. For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Chris Hand
2 Reason for the notification
a) Position/Status: Executive Chairman
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 946,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
946,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Chris Yates
2 Reason for the notification
a) Position/Status: Chief Commercial Officer / President, Abingdon Health USA
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 555,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
555,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Tom Hayes
2 Reason for the notification
a) Position/Status: Chief Financial Officer
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 660,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
660,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Mark Jones
2 Reason for the notification
a) Position/Status: Chief Operating Officer
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 300,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Nina Garrett
2 Reason for the notification
a) Position/Status: Chief Technical Officer
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 300,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Candice Vendettuoli
2 Reason for the notification
a) Position/Status: Director of QARA
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 300,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Natalie Thrush
2 Reason for the notification
a) Position/Status: Chief of Staff / Head of HR
b) Initial Notification/Amendment: Initial Notification
3 Details of the issuer, emission allowance market participation, auction
platform, auctioneer or auction monitor
a) Name: Abingdon Health plc
b) LEI: 213800XFI4WV3FBILO20
4. Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a) Description of the financial instrument: Ordinary Shares of 0.025 pence each
Identification code: GB00BLF79J41
b) Nature of the transaction: Award of LTIP Options
c) Price(s) and volume(s): Price(s) Volume(s)
Nil 300,000
d) Aggregated volume: See above
Price:
e) Date of the Transaction: 3 December 2025
f) Place of the Transaction: Outside a trading venue
4.
Details of transaction(s); section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUPGBWPUPAPPW
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Abingdon Health
See all newsREG - Abingdon Health PLC - Vesting and Award of Options under LTIP
AnnouncementREG - Abingdon Health PLC - Holding(s) in Company
AnnouncementREG - Abingdon Health PLC - Notice of AGM & Publication of 2025 Annual Report
AnnouncementREG - Abingdon Health PLC - Final Results
AnnouncementREG - Abingdon Health PLC - c.US$2m multiplex diagnostic test contract win
Announcement